Vertex Pharmaceuticals Incorporated (VRTX)
Largest Insider Buys in Sector
VRTX Stock Price History Chart
VRTX Stock Performance
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical …
Insider Activity of Vertex Pharmaceuticals Incorporated
Over the last 12 months, insiders at Vertex Pharmaceuticals Incorporated have bought $0 and sold $107.82M worth of Vertex Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Vertex Pharmaceuticals Incorporated have bought $4.09M and sold $96.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $1.96M was made by Kewalramani Reshma (CEO & President) on 2021‑08‑19.
List of Insider Buy and Sell Transactions, Vertex Pharmaceuticals Incorporated
| 2024-11-15 | Sale | EVP, Chief Scientific Officer | 15 <0.0001% | $478.56 | $7,178 | -3.20% | ||
| 2024-11-11 | Sale | EVP & Chief Financial Officer | 3,000 0.0012% | $518.27 | $1.55M | -7.18% | ||
| 2024-11-08 | Sale | CEO & President | 15,198 0.0059% | $515.00 | $7.83M | -7.53% | ||
| 2024-10-02 | Sale | EVP and Chief Legal Officer | 999 0.0004% | $461.66 | $461,198 | +3.03% | ||
| 2024-08-30 | Sale | Executive Chairman | 3,784 0.0015% | $499.00 | $1.89M | -4.20% | ||
| 2024-08-30 | Sale | director | 646 0.0003% | $500.00 | $323,000 | -4.20% | ||
| 2024-08-08 | Sale | director | 1,292 0.0005% | $466.29 | $602,447 | +2.56% | ||
| 2024-08-07 | Sale | EVP and CMO | 2,280 0.0009% | $476.75 | $1.09M | +2.39% | ||
| 2024-08-01 | Sale | director | 5,295 0.0021% | $508.00 | $2.69M | -5.78% | ||
| 2024-07-30 | Sale | CEO & President | 15,202 0.0059% | $505.00 | $7.68M | +0.15% | ||
| 2024-07-24 | Sale | EVP and CMO | 2,280 0.0009% | $488.46 | $1.11M | +0.78% | ||
| 2024-07-22 | Sale | CEO & President | 15,202 0.0059% | $497.00 | $7.56M | -3.61% | ||
| 2024-07-10 | Sale | EVP and CMO | 2,280 0.0009% | $487.34 | $1.11M | 0.00% | ||
| 2024-06-26 | Sale | EVP and CMO | 2,280 0.0009% | $471.72 | $1.08M | +0.98% | ||
| 2024-06-12 | Sale | EVP and CMO | 2,280 0.0009% | $478.00 | $1.09M | +0.46% | ||
| 2024-06-12 | Sale | EVP, Chief Technical Ops. Off. | 7,288 0.0028% | $478.00 | $3.48M | +0.46% | ||
| 2024-06-03 | Sale | EVP, Chief Reg. & Quality Off. | 2,175 0.0008% | $460.00 | $1M | +1.73% | ||
| 2024-06-03 | Sale | EVP & Chief Financial Officer | 3,250 0.0012% | $460.00 | $1.5M | +1.73% | ||
| 2024-05-31 | Sale | EVP, Chief Reg. & Quality Off. | 2,250 0.0009% | $445.00 | $1M | +5.05% | ||
| 2024-05-30 | Sale | EVP, Chief Reg. & Quality Off. | 2,350 0.0009% | $439.11 | $1.03M | +7.91% |
Insider Historical Profitability
| Kewalramani Reshma | CEO & President | 75772 0.0294% | $451.27 | 1 | 27 | +20.8% |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 55325 0.0215% | $451.27 | 1 | 103 | +5.21% |
| SACHS BRUCE I | director | 40000 0.0155% | $451.27 | 7 | 33 | +20.85% |
| LEIDEN JEFFREY M | Executive Chairman | 9994 0.0039% | $451.27 | 2 | 52 | <0.0001% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 2.0895% | $451.27 | 4 | 0 | +14.31% |
Institutional Investor Ownership
| Capital World Investors | $10.69B | 9.91 | 25.57M | +17.25% | +$1.57B | 1.77 | |
| The Vanguard Group | $9.48B | 8.79 | 22.68M | +1.77% | +$164.84M | 0.18 | |
| BlackRock | $9.18B | 8.51 | 21.96M | +0.36% | +$33.23M | 0.2 | |
| State Street | $5.02B | 4.65 | 12.01M | -0.64% | -$32.33M | 0.21 | |
| Fidelity Investments | $4.46B | 4.14 | 10.67M | -17.77% | -$963.93M | 0.3 |